Stéphane Bancel is the CEO of Moderna Inc., a leading biotechnology company known for mRNA technology, especially its COVID-19 vaccine. He joined Moderna in October 2011 and has played a crucial role in shaping the company's vision and strategy. Bancel...

Current Market Cap

$24.50B

Number of Employees

5.6K

Total Compensation

2019 - 2023

Trending down by -9.67% last year
Showing total compensation for the last 2019 - 2023

Stock

Up by 0.00% last year

Salary

Up by 5.00% last year

Bonus

Down by -29.13% last year

Other

Up by 26.18% last year

Year

2023

Total Compensation

$4.56M

Salary

$1.58M

Board Justification

The compensation philosophy is focused on performance-based incentives to align with company performance and shareholder interests.

Bonus

$1.91M

Board Justification

Based on target of 150% of salary, with 81% payout, reflecting 90% individual assessment.

Other

$1.07M

Board Justification

Includes 401(k) match, security services, and other benefits.

Restricted Stock

$0.00(0 RSU)

Board Justification

No stock grants vested in 2023.

Performance Metrics

Performance metrics include product sales from COVID-19 vaccines, operating income, and total shareholder return.

SEC Filing

From March 21, 2024

Stéphane Bancel

CEO of Moderna

M

Education

MBA from Harvard Business School; Master's in Management from the Ecole Centrale Paris.

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Born

April 20, 1972 - 52 years ago

Is Founder?

No

Current Tenure

11 years 0 months (Oct 2013 - Present)

Previous Experience

CEO of Moderna, Inc. since 2013; previously held various roles at BioMérieux and Eli Lilly.

View Holdings

Insider Holdings of Stéphane Bancel

MRNA

$787.96M

-$1.60B (-66.99%)

Last Insider Trade

MRNA

$2.34M

MRNA at $88.88/share

Feb 14, 2024

Sale